Search

Your search keyword '"Darr C"' showing total 144 results
Start Over Author "Darr C"
144 results on '"Darr C"'

3. Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination

Author

Aydogdu, C., primary, Paffenholz, P., additional, Stelmach, R., additional, Schlack, K., additional, Roghmann, F., additional, Handke, A., additional, Mandal, S., additional, Schnabel, M., additional, Merseburger, A., additional, Ivanyi, P., additional, Tschäbitz, S., additional, Darr, C., additional, Grünwald, V., additional, Stief, C.G., additional, and Casuscelli, J., additional

Published
2024
Full Text
View/download PDF

4. The more you see the more you miss. PSMA PET/CT is still affected by a substantial risk of underestimation in prostate cancer patients undergoing radical prostatectomy

Author

Zaurito, P., primary, Barletta, F.M., additional, Gandaglia, G., additional, Rajwa, P., additional, Gomez Rivas, J., additional, Soeterik, T.F.W., additional, Bianchi, L., additional, Kesch, C., additional, Darr, C., additional, Guo, H., additional, Moreno-Sierra, J., additional, Marra, G., additional, Joniau, S., additional, Brunocilla, E., additional, Mattei, A., additional, Dal Moro, F., additional, Fiori, C., additional, Porpiglia, F., additional, Picchio, M., additional, Chiti, A., additional, Van Den Bergh, R., additional, Shariat, S.F., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

5. External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET

Author

Barletta, F.M., primary, Gandaglia, G., additional, Scuderi, S., additional, Robesti, D., additional, Rajwa, P., additional, Soeterik, T.F.W., additional, Bianchi, L., additional, Meijer, D., additional, Darr, C., additional, Guo, H., additional, Zattoni, F., additional, Fendler, W., additional, Marra, G., additional, Joniau, S., additional, Schiavina, R., additional, Mattei, A., additional, Fiori, C., additional, Porpiglia, F., additional, Picchio, M., additional, Van Den Bergh, R., additional, Shariat, S.F., additional, Chiti, A., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

6. Oncological outcomes of pN1 prostate cancer patients treated with radical prostatectomy: Does molecular imaging have a prognostic impact? Results of a large, multi-institutional series

Author

Barletta, F.M., primary, Gandaglia, G., additional, Rajwa, P., additional, Gomez-Rivas, J., additional, Afferi, L., additional, Kesch, C., additional, Darr, C., additional, Zhuang, J., additional, Zattoni, F., additional, Lanzafame, H., additional, Marra, G., additional, Huebner, N., additional, Joniau, S., additional, Cabrera, M., additional, Brunocilla, E., additional, Mattei, A., additional, Fiori, C., additional, Checcucci, E., additional, Picchio, M., additional, Chiti, A., additional, Van Den Bergh, R., additional, Shariat, S.F., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

7. Can we rely on available models predicting pathological outcomes in prostate cancer patients staged with 68-Ga PSMA-PET/CT? External validation of the existing nomograms for extracapsular extension and seminal vesicle invasion at radical prostatectomy and development of a novel tool including intraprostatic SUVmax

Author

Scuderi, S.L.A., primary, Rajwa, P., additional, Gomez-Rivas, J., additional, Bianchi, L., additional, Kesch, C., additional, Darr, C., additional, Guo, H., additional, Zhuang, J., additional, Zattoni, F., additional, Fendler, W., additional, Marra, G., additional, Huebner, N., additional, Joniau, S., additional, Schiavina, R., additional, Mattei, A., additional, Fiori, C., additional, Porpiglia, F., additional, Picchio, M., additional, Chiti, A., additional, Van Den Bergh, R., additional, Shariat, S., additional, Montorsi, F., additional, Briganti, A., additional, and Gandaglia, G., additional

Published
2024
Full Text
View/download PDF

9. Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma – real world data from a retrospective multi-center analysis

Author

Stelmach, R., primary, Schlack, K., additional, Neuberger, S., additional, Muehle, C., additional, Darr, C., additional, Reichert, M., additional, Flegar, L., additional, Zengerling, F., additional, Casuscelli, J., additional, Cox, A., additional, Nestler, T., additional, Egenolf, T., additional, Brehmer, B., additional, Vallet, S., additional, Ivanyi, P., additional, Rehlinghaus, M., additional, Neuberger, M., additional, Paffenholz, P., additional, Grünwald, V., additional, and Zschäbitz, S., additional

Published
2023
Full Text
View/download PDF

12. Cabozantinib + Nivolumab bei erwachsenen Patienten mit fortgeschrittenem oder metastasiertem Nierenzellkarzinom. Eine retrospektive, nicht-interventionelle Studie in einem realen Patientenkollektiv

Author

Hilser, T, Darr, C, Niegisch, G, Schnabel, MJ, Foller, S, Häuser, L, Zschäbitz, S, Lewerich, J, Anders-Meyn, M, Ivanyi, P, Grünwald, V, Hilser, T, Darr, C, Niegisch, G, Schnabel, MJ, Foller, S, Häuser, L, Zschäbitz, S, Lewerich, J, Anders-Meyn, M, Ivanyi, P, and Grünwald, V

Published
2023

15. Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer

Author

Scuderi, S.L.A., primary, Gandaglia, G., additional, Barletta, F., additional, Bianchi, L., additional, Zattoni, F., additional, Dal Moro, F., additional, Reitano, G., additional, Rajwa, P., additional, Hübner, N., additional, Shariat, S., additional, Kesch, C., additional, Darr, C., additional, Fendler, W., additional, Gomez-Rivas, J., additional, Moreno-Sierra, J., additional, Marra, G., additional, Guo, H., additional, Zhuang, J., additional, Amparore, D., additional, Checcucci, E., additional, Porpiglia, F., additional, Schiavina, R., additional, Brunocilla, E., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2023
Full Text
View/download PDF

16. Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric stricture

Author

Krafft, Ulrich, Mahmoud, O., Heß, Jochen A., Radtke, Patrick, Panic, Andrej, Püllen, Lukas, Darr, C., Kesch, C., Szarvas, Tibor, Rehme, Christian R., Hadaschik, Boris, and Tschirdewahn, Stephan

Subjects
Medizin, Surgery
Abstract

Purpose Ureteroenteric anastomosis after cystectomy is usually performed using the Bricker or Wallace technique. Deterioration of renal function is the most common long-term complication of urinary diversion (UD). To improve surgical care and optimize long-term renal function, we compared the Bricker and Wallace anastomotic techniques and identified risk factors for ureteroenteric strictures (UES) in patients after cystectomy. Material and methods Retrospective, monocentric analysis of 135 patients who underwent cystectomy with urinary diversion at the University Hospital Essen between January 2015 and June 2019. Pre- and postoperative renal function, relevant comorbidities, prior chemo- or radiotherapy, pathological findings, urinary diversion, postoperative complications, and ureteroenteric strictures (UES) were analyzed. Results Of all 135 patients, 69 (51.1%) underwent Bricker anastomosis and 66 (48.9%) Wallace anastomosis. Bricker and Wallace groups included 134 and 132 renal units, respectively. At a median follow-up of 14 (6–58) months, 21 (15.5%) patients and 30 (11.27%) renal units developed UES. We observed 22 (16.6%) affected renal units in Wallace versus 8 (5.9%) in Bricker group (p p OR 9.74, 95% CI 2–46.2, p = 0.004; OR 4.01, 95% CI 1.36–11.82, p = 0.013). Conclusion The results of this study show no significant difference in ureteroenteric anastomotic techniques with respect to UES development regarding individual patients but suggest a higher risk of bilateral UES formation in patients undergoing Wallace anastomosis. This is reflected in the increased UES rate under consideration of the individual renal units.

Published
2021

17. 1759P Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort

Author

Darr, C., primary, Zschäbitz, S., additional, Niegisch, G., additional, Roghmann, F., additional, Ivanyi, P., additional, Zengerling, F., additional, Paffenholz, P., additional, Biernath, N., additional, Klee, M., additional, Klümper, N., additional, Tauber, R.L., additional, Hadaschik, B.A., additional, Hilser, T., additional, and Grünwald, V., additional

Published
2022
Full Text
View/download PDF

19. Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort

Author

Darr, C., Zschaebitz, S., Niegisch, G., Roghmann, F., Ivanyi, P., Zengerling, F., Paffenholz, P., Biernath, N., Klee, M., Kluemper, N., Tauber, R. L., Hadaschik, B. A., Hilser, T., Gruenwald, V., Darr, C., Zschaebitz, S., Niegisch, G., Roghmann, F., Ivanyi, P., Zengerling, F., Paffenholz, P., Biernath, N., Klee, M., Kluemper, N., Tauber, R. L., Hadaschik, B. A., Hilser, T., and Gruenwald, V.

Published
2022

25. Robot-assisted partial nephrectomy for multiple renal tumors – a multicenter analysis

Author

Harke, N.N., primary, Schiefelbein, F., additional, Schneller, A., additional, Schoen, G., additional, Wiesinger, C.G., additional, Pfuner, J., additional, Falkensammer, E., additional, Gilbert, N., additional, Eraky, A., additional, Zimmermanns, V., additional, Paramythelli, I., additional, Hadaschik, B.A., additional, Radtke, J.P., additional, Darr, C., additional, Kriegmair, M.C., additional, Flintrop, M., additional, Wolters, M., additional, Faraj Tabrizi, P., additional, Kuczyk, M.A., additional, and Osmonov, D., additional

Published
2022
Full Text
View/download PDF

26. 679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)

Author

Darr, C., primary, Zschäbitz, S., additional, Ivanyi, P., additional, Wirth, M., additional, Staib, P., additional, Schostak, M., additional, Müller, L., additional, Metz, M., additional, Bergmann, L., additional, Steiner, T., additional, Lorch, A., additional, Schütt, P., additional, Rafiyan, M-R., additional, Hellmis, E., additional, Hinke, A., additional, Mänz, M., additional, Meiler, J., additional, Kretz, T., additional, Flörcken, A., additional, and Grünwald, V., additional

Published
2021
Full Text
View/download PDF

27. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy: A prospective, randomized comparison to conventional target biopsy

Author

Saner, Y., primary, Wiesenfarth, M., additional, Tschirdewahn, S., additional, Püllen, L., additional, Bonekamp, D., additional, Krafft, U., additional, Kesch, C., additional, Darr, C., additional, Forsting, M., additional, Umutlu, L., additional, Hadaschik, B.A., additional, and Radtke, J.P., additional

Published
2021
Full Text
View/download PDF

28. Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions : A Single Center Experience

Author

Krafft, Ulrich, Hirner (L.), Lucas, Darr, C., Mahmoud, O., Hadaschik, Boris, and Rehme, Christian R.

Subjects
Medizin
Abstract

CA Krafft Introduction: To evaluate efficacy and safety of Botulinum Toxin A (Botox) injection in the detrusor for day-time lower urinary tract conditions with mainly overactive symptoms, we analyzed our uropediatric Botox-treated collective. Materials and Methods: 21 Children who received a Botox treatment in our hospital between 2016 and 2020 for refractory day-time lower urinary tract conditions with mainly overactive symptoms with conclusive follow up were analyzed. In all cases we applicated 100 IU Botox. Results: Mean age of patients was 9,19 (±3,0). In 8/21 cases a preoperative urodynamic assessment was available. We reached a median follow up of 289 days (range 34-750). Mean bladder capacity increased from 157 ml (±18.4) to 213 ml (±24.5) (p = 0.001). Mean voiding frequency decreased from 7.4 (±0.61) to 6.2 (±0.55) (p = 0.015). 13/21 Patients (61.9%) encountered a partial or complete therapy response while 8/21 Children (38.1%) showed a therapy failure. Within the responder group, 8/13 Children (61, 5%) experienced an ongoing response. However, 5 Children relapsed on average in 176 days (±45, 5). 3 Children received a repeated injection of Botox. We observed no serious side effects. Discussion/Conclusion: Even though pediatric Botox therapy still lacks standardization; our study indicates a safe and effective use for day-time lower urinary tract conditions with mainly overactive symptoms in children who are resistant to common treatments. Moreover, we found a one-time injection in most cases to be sufficient to improve symptoms in the long term.

Published
2021

29. Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH)

Author

Darr, C., Zschäbitz, S., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Müller, L., Metz, M., Bergmann, L., Steiner, T., Lorch, A., Schütt, P., Rafiyan, M-R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Flörcken, A., and Grünwald, V.

Subjects
Medizin
Published
2021

30. P151 - Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma – real world data from a retrospective multi-center analysis

Author

Stelmach, R., Schlack, K., Neuberger, S., Muehle, C., Darr, C., Reichert, M., Flegar, L., Zengerling, F., Casuscelli, J., Cox, A., Nestler, T., Egenolf, T., Brehmer, B., Vallet, S., Ivanyi, P., Rehlinghaus, M., Neuberger, M., Paffenholz, P., Grünwald, V., and Zschäbitz, S.

Published
2023
Full Text
View/download PDF

32. 1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)

Author

Darr, C., Ivanyi, P., Wirth, M., Zschäbitz, S., Schostak, M., Mueller, L., Steiner, T., Welslau, M.K., Schuett, P., Lorch, A., Rafiyan, M-R., Hellmis, E., Meiler, J., Kretz, T., Loidl, W.C., Floercken, A., Stöhr, C.G., Eckstein, M., Hartmann, A., and Grünwald, V.

Published
2023
Full Text
View/download PDF

33. Die Rolle von MRT-basierten 3D-Druckmodellen der Prostata und von Prostatakarzinomläsionen für die Durchführung intraoperativer Schnellschnitte und der radikalen Prostatektomie – eine prospektive Machbarkeitsstudie

Author

Darr, C, Finis, F, Kesch, C, Wiesenfarth, M, Giganti, F, Tschirdewahn, S, Forsting, M, Wetter, A, Reis, H, Hadaschik, BA, Haubold, J, and Radtke, JP

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung und Zielsetzung: Die präzise Kenntnis der Lage von Indextumoren innerhalb der Prostata (Läsion mit dem höchsten Gleason Score und/oder dem größten Volumen) und ihrer Nähe zur Prostatakapsel und den neurovaskulären Bündeln hat sowohl für intraoperative[zum vollständigen Text gelangen Sie über die oben angegebene URL], 66. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2020
Full Text
View/download PDF

46. Assessment of the Inter-Annual Variability of the Global Horizontal Irradiance in the Atacama Desert of Chile

Author

Darez, P., Baudry, J., and Darr, C.

Subjects
NEW MATERIALS AND CONCEPTS FOR SOLAR CELLS AND MODULES, Fundamental Material Studies
Abstract

31st European Photovoltaic Solar Energy Conference and Exhibition; 20-24, The inter-annual variability (IAV) of the solar resource is an important uncertainty component in annual energy production (AEP) estimates of photovoltaic (PV) plants. Based on studies in the Mediterranean and Black Sea region, a figure of 4 to 6% is sometimes used by consultants. For the extremely arid climates in the Atacama Desert in the North of Chile such generic values are expected to unnecessarily penalise developers seeking project financing. In the absence of reliable and consistent long-term ground measurements for this region, and based on previous in-house validation work and industry experience, long-term mesoscale satellite-derived datasets from the SolarGIS® database were found to be the best available data source to estimate the IAV of the global horizontal irradiance (GHI). It was found that none of the 14 sample sites considered in this study displayed an IAV exceeding 2%. While this result is subject to limitations, the observed performance of the model relative to measured data suggests that the uncertainty in the IAV value is small compared to the systematic error that otherwise arises from using a 4 to 6% generic figure for sites in the Atacama.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results